Steven Maxwell, DO
Critical Care Medicine · Morgantown, WVNPI 1679652986
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 25.7% of the total. Reporting peaked in 2019 at $466 and has fallen 89.2% since, to $50 in 2023. That places this record below the midpoint for critical care medicine clinicians in WV, where the typical reported total is $850.
Across 30 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$168
- AstraZeneca$153
- Intuitive Surgical$148
- Boehringer Ingelheim$95
- Sunovion Pharmaceuticals Inc.$19
- Merck$18
- plus $54 from 4 others
What the payments were for
- Food & beverage$654100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 9 | $168 |
| AstraZeneca | 9 | $153 |
| Intuitive Surgical | 1 | $148 |
| Boehringer Ingelheim | 5 | $95 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $18 |
| United Therapeutics Corporation | 1 | $16 |
| Novartis | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$654 in reported general payments places this provider in the 45th percentile of 29 critical care medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $157,175 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $38,351 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $21,698 |
| Advair HfaFluticasone Propion/Salmeterol | 40 | $15,915 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $15,540 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $15,066 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $14,856 |
| Spiriva HandihalerTiotropium Bromide | 18 | $14,035 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $13,950 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,432 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 50 | $5,877 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $5,595 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 72 | $2,436 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $2,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $168 | $79,221112 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $153 | $30,39676 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $95 | $23,49827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 29 critical care medicine providers in West Virginia.
Other critical care medicine in Morgantown
- Parag ChaudhariMorgantown$8K
- Joshua BrewerMorgantown$72
- Veena NandwaniMorgantown$64
- Phillip CoxSouth Charleston$20K
- Kevin EgglestonSouth Charleston$13K
- Robby KeithSouth Charleston$12K
- James PerrySouth Charleston$12K
- Tamejiro TakuboSouth Charleston$10K
- William WadeSouth Charleston$7K
- William BeamHuntington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.